نتائج البحث

Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

• Authors : Goodman, Shaun G; Steg, Philippe Gabriel; Szarek, Michael

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Clinical Trials and Supportive Activities

• Source: European Heart Journal - Cardiovascular Pharmacotherapy. 10(4)

تفاصيل العنوان

Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic Syndrome

• Authors : Regeneron Pharmaceuticals; Aventis Pharmaceuticals; Gloria Vega, Principal Investigator at Dallas VA Medical Center

• Source: Effect of PCSK9-Antibody (Alirocumab) on Dyslipidemia Secondary to Nephrotic SyndromeVega GL, Grundy SM. Lovastatin therapy in nephrotic hyperlipidemia: effects on

تفاصيل العنوان

Effect of alirocumab on individuals with type 2 diabetes, high triglycerides, and low high-density lipoprotein cholesterol.

• Authors : Colhoun HM; The Institute of Genetics and Molecular Medicine, University of Edinburgh, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU, UK. .; Leiter LA

Subjects: PCSK9 Inhibitors*; Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2020 Feb 08; Vol. 19 (1), pp. 14. Date of Electronic Publication: 2020 Feb 08.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI (EPIC STEMI)

• Source: Effects of Acute, Rapid Lowering of Low Density Lipoprotein Cholesterol With Alirocumab in Patients With ST Segment Elevation Myocardial Infarction Undergoing Primary

تفاصيل العنوان

Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.

• Authors : Ray KK; Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College, Kensington, London, SW7 2AZ, UK. .; Del Prato S

Subjects: Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/Antibodies, Monoclonal, Humanized/*therapeutic use ; Anticholesteremic Agents/Anticholesteremic Agents/Anticholesteremic Agents/*therapeutic use ; Atherosclerosis/Atherosclerosis/Atherosclerosis/*drug therapy

• Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2019 Nov 09; Vol. 18 (1), pp. 149. Date of Electronic Publication: 2019 Nov 09.Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840

تفاصيل العنوان

Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS)

• Source: Non-interventional Study on the Monthly Administration of 300 mg AliRocumab (PRALUENT®) With the 2 ml SYDNEY Auto-injector (MARS-NIS)

تفاصيل العنوان

Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes

• Authors : Roe, Matthew T.; Hagström, Emil; Zobouyan, Isabelle

Subjects: alirocumab; acute coronary syndrome; dyslipidemias

• Source: Circulation. 140(19):1578-1589

تفاصيل العنوان

Early Alirocumab to Reduce LDL-C in Myocardial Infarction (EARLY)

• Authors : Regeneron Pharmaceuticals; Baim Institute for Clinical Research

• Source: Early Alirocumab to Reduce LDL-C in Myocardial Infarction

تفاصيل العنوان

Efficacy and Safety of Alirocumab Versus Usual Care on Top of Maximally Tolerated Statin Therapy in Patients With Type 2 Diabetes and Mixed Dyslipidemia (ODYSSEY DM-Dyslipidemia)

• Authors : Regeneron Pharmaceuticals

• Source: A Randomized, Open-Label, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab Versus Usual Care in Patients With Type 2 Diabetes and Mixed

تفاصيل العنوان

Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: Pooled data from 10 phase 3 trials

• Authors : Henry, Robert R; Müller‐Wieland, Dirk; Taub, Pam R

Subjects: Biomedical and Clinical Sciences; Clinical Sciences; Cardiovascular

• Source: Diabetes Obesity and Metabolism. 20(7)

تفاصيل العنوان